Skip to content

Teriparatide

    Brands

    DEA Class; Rx

    Common Brand Names; Forteo, parathyroid hormone, Bonsity

    • Parathyroid Hormone Analogs

    Recombinant human parathyroid hormone
    Used for the treatment of osteoporosis in patients with high risk of fracture
    Boxed warning regarding the risk of osteosarcoma; not recommended for use in patients at risk for osteosarcoma

    Treatment of postmenopausal women with osteoporosis at high risk for fracture who have failed or are intolerant to other available osteoporosis therapy; reduces risk of vertebral and nonvertebral fractures

    Increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture, or have failed or are intolerant to other available therapy

    Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (prednisone ≥5 mg/day) at high risk for fracture, or have failed or are intolerant to other available therapy

    Hypersensitivity

    • Pain (21.3%)
    • Arthralgia (10.1%)
    • Rhinitis (9.6%)
    • Asthenia (8.7%)
    • Nausea (8.5%)
    • Dizziness (8%)
    • Headache (7.5%)
    • Hypertension (7.1%)
    • Increased cough (6.4%)
    • Pharyngitis (5.5%)
    • Constipation (5.4%)
    • Dyspepsia (5.2%)
    • Diarrhea (5.1%)
    • Rash (4.9%)
    • Insomnia (4.3%)
    • Depression (4.1%)
    • Pneumonia (3.9%)
    • Vertigo (3.8%)
    • Dyspnea (3.6%)
    • Neck pain (3%)
    • Vomiting (3%)
    • Syncope (2.6%)
    • Leg cramps (2.6%)
    • Angina pectoris (2.5%)
    • Gastrointestinal disorder (2.3%)
    • Tooth disorder (2%)

    Transient orthostatic hypotension may occur with initial doses

    May exacerbate urolithiasis; consider risk/benefit in patients with active or recent urolithiasis

    There are no available data on use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; consider discontinuing drug when pregnancy is recognized

    Not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on breastfed infant; because of potential for osteosarcoma shown in animal studies, advise patients that breastfeeding is not recommended during therapy

    Adults

    20 mcg/day subcutaneously for osteoporosis.

    Geriatric

    20 mcg/day subcutaneously for osteoporosis.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Teriparatide rDNA origin

    prefilled injectable pen

    • 250mcg/mL (2.4 mL [Forteo, Bonsity])